Detailed description page of SalivaDB

This page displays user query in tabular form.

SAL_16790 details
Primary information
SALIDSAL_16790
Biomarker nameAcetate
Biomarker TypeNA
Sampling MethodA total of 56 samples of stimulated saliva were collected from 14 female pSS patients during four laboratory visits within 20 weeks
Collection MethodStimulated whole mouth saliva (SWMS) was collected by chewing paraffin wax (Orion Diagnostica, Espoo, Finland; 1 g) for 30 s and all produced saliva was collected over a 5-min period.
Analysis MethodNMR
Collection SiteSaliva
Disease CategoryAutoimmune Disorder
Disease/ConditionSjogren's Syndrome
Disease SubtypeNA
Fold Change/ ConcentrationNA
Up/DownregulatedNA
ExosomalNA
OrganismHomo sapiens
PMID33116006
Year of Publication2020
Biomarker ID175
Biomarker CategoryMetabolite
SequenceCC(=O)[O-]
Title of studyVariability of salivary metabolite levels in patients with Sjögren's syndrome
Abstract of studyPURPOSE: To investigate inter- and intra-individual variation in the levels and outputs (concentration multiplied by salivary flow rate) of salivary metabolites in patients with primary Sjögren's syndrome (pSS).METHODS: A total of 56 samples of stimulated saliva were collected from 14 female pSS patients during four laboratory visits within 20 weeks and analyzed using proton nuclear magnetic resonance spectroscopy. Single saliva samples from each of 15 controls were also analyzed.RESULTS: Among 21 quantified metabolites, choline was significantly elevated in the pSS patients at each time point (P ≤ 0.015), taurine at the last three time points (P ≤ 0.013), alanine at the last two time points (P ≤ 0.007) and glycine at the last time point (P = 0.005). Inter-individual variation in metabolite concentrations was generally larger among the patients than among the controls, and significantly large variations were observed for glycine (P ≤ 0.007, all time points), choline (P ≤ 0.033, three last time points) and alanine (P = 0.028, baseline). Metabolite output analysis showed that choline had the lowest intra-patient variation.CONCLUSION: In spite of considerable intra- and inter-individual variation, levels and outputs of specific metabolites in patients with pSS differ from those in controls, and may be potentially applicable as new biological markers for monitoring of the response to treatment.